Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)

Alessandra Arcelli, Alessandra Guido, Milly Buwenge, Nicola Simoni, Renzo Mazzarotto, Gabriella Macchia, Francesco Deodato, Savino Cilla, Pierluigi Bonomo, Valerio Scotti, Liliana Belgioia, Giorgio Tolento, Francesco Cellini, Elisa Grassi, Mariacristina Di Marco, Riccardo Casadei, Alessio G. Morganti, Silvia Cammelli

Research output: Contribution to journalArticle

Abstract

Aim: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters’ impact on these outcomes was assessed. Materials and Methods: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. Results: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). Conclusion: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC.

Original languageEnglish
Pages (from-to)465-472
Number of pages8
JournalAnticancer Research
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 1 2020

Keywords

  • Chemotherapy
  • Dose effect
  • Pancreatic cancer
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)'. Together they form a unique fingerprint.

  • Cite this

    Arcelli, A., Guido, A., Buwenge, M., Simoni, N., Mazzarotto, R., Macchia, G., Deodato, F., Cilla, S., Bonomo, P., Scotti, V., Belgioia, L., Tolento, G., Cellini, F., Grassi, E., Di Marco, M., Casadei, R., Morganti, A. G., & Cammelli, S. (2020). Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1). Anticancer Research, 40(1), 465-472. https://doi.org/10.21873/anticanres.13975